Skip to main content

Table 1 Characteristics of patients with pT0 prostate cancer

From: The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer

Patient number

Age

PSA (ng/mL))

Duration of NHT

Clinical stage

GS

Number of positive cores on biopsy

Maximal tumor length on biopsy (mm)

Duration of follow-up

Baseline

After NHT

1

66

24.6

<0.1

6 months

T2cNoMo

7

6

10.0

48

2

77

55.3

0.3

3 months

T3aN0M0

6

3

3.0

60

3

66

20.9

<0.1

6 months

T3aN0M0

7

3

21.0

80

4

76

6.18

<0.1

3 months

T2cNoMo

7

8

12.0

74

5

73

9.4

<0.1

12 months

T3aN0M0

7

8

5.0

57

6

74

19.38

<0.1

6 months

T3aN0M0

8

6

10.0

6

  1. PSA prostate-specific antigen, NHT neoadjuvant hormonal therapy, GS Gleason score